Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen – The New York Times

1. Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen The New York Times
2. House investigation says FDA approval process of Alzheimer’s drug was ‘rife with irregularities’ CNN
3. House investigation faults FDA, Biogen for Alzheimer’s drug approval The Washington Post
4. Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds STAT
5. FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimer’s Drug The Wall Street Journal
6. View Full Coverage on Google News

Read original article here